ProQR Therapeutics N.V. (Nasdaq: PRQR) announced positive target engagement data from its ongoing Phase 1 clinical study of AX-0810, an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE